{
  "id": "fda_guidance_chunk_0117",
  "title": "Introduction - Part 117",
  "text": "of Translational Sciences in the Center for Drug Evaluation and Research in cooperation with the Center for Biologics Evaluation and Research at the Food and Drug Administration. 2 The term drug, as used in this guidance, refers to both human drugs and biological products unless otherwise specified. 3 Clinical trial has the same meaning as the term clinical investigation as the latter is defined in FDA regulations (see 21 CFR 312.3(b)). Contains Nonbinding Recommendations 2 Issues in Clinical Trials (May 2001), respectively.4 Additional FDA guidances cover other 30 specific topics that may be of specialized interest.5,6,7,8 31 32 In general, FDA’s guidance documents do not establish legally enforceable responsibilities. 33 Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only 34 as recommendations, unless specific regulatory or statutory requirements are cited. The use of 35 the word should in Agency guidances means that something is suggested or recommended, but 36 not required. 37 38 39 II. BACKGROUND 40 41 Section 526(a)(2)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) defines a rare 42 disease or condition, in part, as a disease or condition that “affects less than 200,000 persons in 43 the United States.”9 Most rare diseases, however, affect far fewer people. The sponsor of an 44 orphan drug (a drug intended for use in a rare disease or condition10) may be eligible for orphan-45 drug designation and certain financial incentives intended to help make developing drugs for 46 small numbers of patients financially viable;11 however, the Orphan Drug Act does not create a 47 statutory standard for the approval of orphan drugs that is different from the standard for 48 approval of drugs for common diseases or conditions. 49 50 4 We update guidances periodically. For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/regulatory-information/search-fda-guidance-documents. 5 See the ICH guidance for industry E8(R1) General Considerations for Clinical Studies (April 2022). 6 See the guidance for industry Adaptive Designs for Clinical Trials of Drugs and Biologics (November 2019). 7 See the draft guidance for industry Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products (February 2023). When final, this guidance will represent the FDA’s current thinking on this topic. For the most recent version of",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 155904,
  "end_pos": 157440,
  "tokens": 512,
  "tags": [
    "design",
    "regulatory",
    "clinical_trial"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "recommendation",
  "created_at": "2025-10-23T02:25:44.684Z"
}